Cambrex set to acquire Halo Pharma for $425m to expand into finished dosage form market
In a significant expansion of its capabilities, Cambrex Corporation has announced its agreement to acquire Halo Pharma, a US-based contract development and manufacturing organization (CDMO), for $425 million. This strategic move propels Cambrex into the lucrative finished dosage form CDMO market, complementing its existing strengths in small molecule and generic Active Pharmaceutical Ingredients (APIs). Currently […]